NYSE:MYOV
Delisted
Myovant Sciences Ltd Stock News
$26.98
+0 (+0%)
At Close: Jun 08, 2023
Former Genentech exec looks to replicate that 'magical time' with new biotech model
09:39pm, Monday, 03'rd Feb 2020
Myrtle Potter wants Sumitovant to "keep thinking about complex problems and stay scrappy and stay focused on the programs that make a difference for patients."
Bluebird up 2% premarket on two new bullish calls
01:34pm, Monday, 03'rd Feb 2020
Bluebird bio (NASDAQ:BLUE) initiated with Buy rating and $120 (56% upside) price target at Bank of America. Upgraded to Outperform with a $100 price target at Evercore ISI. Shares up 2% premarket.Ce
Myovant Sciences resumed with a Neutral from Buy at Citi MYOV
11:25am, Monday, 03'rd Feb 2020
Myovant Sciences resumed with a Neutral from Buy at Citi Citi MYOV
Myovant Sciences: Bull And Bear Cases And Investment Decision
10:46am, Monday, 03'rd Feb 2020
I estimate >75% probability of success for SPIRIT 2 and 2 trials for Relugolix in treating endometriosis-associated pain (data in H1 2020). Recent Phase 3 resul
Myovant Sciences Ltd (NYSE:MYOV) Forecasted to Post FY2020 Earnings of ($3.17) Per Share
09:18am, Friday, 31'st Jan 2020
Myovant Sciences Ltd (NYSE:MYOV) – Equities research analysts at Svb Leerink increased their FY2020 EPS estimates for Myovant Sciences in a research note issued to investors on Monday, January 27th.
The "Heavy Menstrual Bleeding (HMB) - Market Insights, Epidemiology and Market Forecast - 2028" drug pipelines has been added to ResearchAndMarkets.com's offering.
Heavy Menstrual Bleeding (HMB) Market Analysis and Forecast 2017-2028
12:50pm, Monday, 27'th Jan 2020
Dublin, Jan. 27, 2020 -- The "Heavy Menstrual Bleeding (HMB) - Market Insights, Epidemiology and Market Forecast - 2028" drug pipelines has been added to.
CEOs of Women’s Health Companies Fight to Open Investment Floodgates
11:00am, Wednesday, 22'nd Jan 2020
Talking about sex with potential investors? For EvoFem Biosciences CEO Saundra Pelletier, it’s the first item on the docket. Her company recently
Top Picks 2020- Myovant Sciences Ltd. MYOV
10:00am, Wednesday, 22'nd Jan 2020
Myovant Sciences Ltd. (MYOV) offers a new drug "pipeline in a pill", asserts biotech expert Jay Silverman, contributing editor to The Medical Technology Stock Letter.
The Cutting Edge Of Systematic Investing
05:48pm, Tuesday, 21'st Jan 2020
Systematic or Quantitative Investing continues to be a bigger part of the market as it delivers stronger market-beating returns fairly consistently. Experts oft
Insider Selling: Myovant Sciences Ltd (NYSE:MYOV) Insider Sells $67,953.60 in Stock
10:34am, Monday, 20'th Jan 2020
Myovant Sciences Ltd (NYSE:MYOV) insider Kim Sablich sold 4,840 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $14.04, for a
Why Myovant Stock Fell 5% in 2019
02:40pm, Monday, 13'th Jan 2020
Shares swung wildly as investors tried to guess at the long-run prospects of promising new drug treatments for prostate cancer.
Myovant Sciences to Present at the 38th Annual J.P. Morgan Healthcare Conference
01:30pm, Monday, 06'th Jan 2020
BASEL, Switzerland, Jan. 06, 2020 -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer,.
Myovant Sciences Confirms Closing of US$400 Million Loan Facility
01:58pm, Monday, 30'th Dec 2019
Myovant confirmed the closing of the previously announced loan facility from Sumitomo Dainippon Pharma, now increased to US$400 million. The post Myovant Sciences Confirms Closing of US$400 Million Lo
Low-interest (3-month LIBOR plus 3%) loan facility from Sumitomo Dainippon Pharma increased to allow repayment of pre-existing debtHiroshi Nomura, President, CEO, and.